Effects of Endometrial Ablation on Treatment Planning in Women With Endometrial Cancer

详细信息    查看全文

• 作者：Erica Argall ; MD^a ; Anna Jovanovic ; MD^b ; Reinaldo Figueroa ; MD^a ; ^{RFiguero@stfranciscare.org" class="auth_mail" title="E-mail the corresponding author} ; Allan Mayer ; DO^a ; Beth Nelson ; MD^a ; Phillip Roland ; MD^a
• 关键词：Endometrial ablation ; Endometrial cancer ; Endometrial histology ; Pre-ablation endometrial biopsy
• 刊名：Journal of Minimally Invasive Gynecology
• 出版年：2016
• 出版时间：1 February 2016
• 年：2016
• 卷：23
• 期：2
• 页码：281-285
• 全文大小：1098 K

文摘

To evaluate effects of endometrial ablation on the staging and treatment planning of postablation endometrial cancer. After authorization from the institutional review board, we performed a retrospective chart review of patients with a history of endometrial ablation and a subsequent diagnosis of endometrial cancer from July 2006 to December 2013. The information obtained included patient's age at time of cancer diagnosis, pre-ablation endometrial biopsy histology, dilation and curettage histology at time of ablation, endometrial biopsy-to-ablation interval, ablation-to-hysterectomy interval, final pathologic diagnosis, Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging, and treatment recommendations for adjuvant therapy. The histopathology was examined by a gynecologic pathologist. The National Comprehensive Cancer Network guidelines were applied to determine need for adjuvant therapy. Six of 490 (1.2%) patients with endometrial cancer were identified to have an antecedent ablation. Mean patient age was 48.2 years (range: 40–53). The time interval from office pre-ablation endometrial sampling to ablation ranged from 1 to 17 months. Four patients (67%) had an undetected endometrial cancer at the time of ablation, despite having benign pre-ablation histology. Following surgical staging, 4 patients (67%) had no evidence of residual carcinoma, and 2 (33%) had evidence of endometrial adenocarcinoma grades 1 to 2. There was no evidence of myometrial invasion in all cases, and a FIGO stage of IA was assigned. No adjuvant therapies were indicated. There have been no documented cancer recurrences, with a follow-up range from 16 to 52 months (average 30.2). Endometrial ablation artifact does not appear to hinder evaluation and treatment planning in the presence of endometrial cancer.